Identifying estrogen-responsive genes is an apparently simple problem. The obvious method to use is to profile gene expression in the presence or absence of estrogen [6]. This can be performed either by expression microarray, which involves the use of tiling oligonucleotide probes and identifying the targets of RNA hybridization, and RNA-seq, which involves fragmenting RNA in cells and sequencing cDNA reverse transcribed from these RNA fragments [7]. However, depending on the time course used in transcriptomic experiments, this will identify both direct estradiol target genes and secondary genes modulated by those direct target genes (see Note 1).
Chromatin immunoprecipitation with massively parallel sequencing (ChIP-seq) is a technique that allows for the genomic localization of nuclear receptor binding [7, 8]. This technique uses the formation of formaldehyde cross bridges between DNA and proteins bound to nucleic acid, followed by selective sequencing of DNA fragments that have been immunoprecipitated by an antibody directed against a protein of interest. In case the of estrogen, fragments that are immunoprecipitated with antibodies against ESR1 or ESR2 can be compared with fragments immunoprecipitated by nonspecific antibodies (input control) or fragments can be compared between samples pre- and posttreatment with estrogen. Stimulation with estrogen (or estrogen receptor agonists) can be problematic as, just as in the case of transcriptomics, the duration of stimulation can be an important consideration in capturing different aspects of receptor binding (see Note 2). Remodeling of the chromatin architecture and the 3D structure of the genome are likely to be complex and time-dependent processes, which mean that the snapshot of estrogen receptor occupancy afforded by ChIP-seq may not always be representative of the underlying biology (see Note 3) [9, 10].
Pinkhasov RM, Shteynshlyuger A, Hakimian P et al (2010) Are men shortchanged on health? Perspective on life expectancy, morbidity, and mortality in men and women in the United States. Int J Clin Pract 64:465–474
Leslie KK, Thiel KW, Reyes HD et al (2013) The estrogen receptor joins other cancer biomarkers as a predictor of outcome. Obstet Gynecol Int 2013:479541
Ross-Innes CS, Stark R, Teschendorff AE et al (2012) Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481:389–393
Michalek RD, Gerriets VA, Nichols AG et al (2011) Estrogen-related receptor-α is a metabolic regulator of effector T-cell activation and differentiation. Proc Natl Acad Sci U S A 108:18348–18353
Welboren W-J, Sweep FCGJ, Span PN, Stunnenberg HG (2009) Genomic actions of estrogen receptor α: what are the targets and how are they regulated? Endocr Relat Cancer 16:1073–1089
Hah N, Danko CG, Core L et al (2011) A rapid, extensive, and transient transcriptional response to estrogen signaling in breast cancer cells. Cell 145:622–634
Handel AE, Disanto G, Ramagopalan SV (2013) Next-generation sequencing in understanding complex neurological disease. Expert Rev Neurother 13:215–227
Carroll JS, Meyer CA, Song J et al (2006) Genome-wide analysis of estrogen receptor binding sites. Nat Genet 38:1289–1297
Fullwood MJ, Liu MH, Pan YF et al (2009) An oestrogen-receptor-alpha-bound human chromatin interactome. Nature 462:58–64
Liu MH, Cheung E (2014) Estrogen receptor-mediated long-range chromatin interactions and transcription in breast cancer. Mol Cell Endocrinol 382:624–632
Giardine B, Riemer C, Hardison RC et al (2005) Galaxy: a platform for interactive large-scale genome analysis. Genome Res 15:1451–1455
Blankenberg D, Von Kuster G, Coraor N et al (2010) Galaxy: a web-based genome analysis tool for experimentalists. Curr Protoc Mol Biol Chapter 19:Unit 19.10.1–21
Goecks J, Nekrutenko A, Taylor J, Galaxy Team (2010) Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences. Genome Biol 11:R86
Sandve GK, Gundersen S, Rydbeck H et al (2010) The Genomic HyperBrowser: inferential genomics at the sequence level. Genome Biol 11:R121
Sandve GK, Gundersen S, Johansen M et al (2013) The Genomic HyperBrowser: an analysis web server for genome-scale data. Nucleic Acids Res 41:W133–W141
Wang S, Sun H, Ma J et al (2013) Target analysis by integration of transcriptome and ChIP-seq data with BETA. Nat Protoc 8:2502–2515
Ramsköld D, Kavak E, Sandberg R (2012) How to analyze gene expression using RNA-sequencing data. Methods Mol Biol 802:259–274
Rougemont J, Naef F (2012) Computational analysis of protein-DNA interactions from ChIPseq data. Methods Mol Biol 786:263–273
Hurtado A, Holmes KA, Geistlinger TR et al (2008) Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 456:663–666
McLean CY, Bristor D, Hiller M et al (2010) GREAT improves functional interpretation of cis-regulatory regions. Nat Biotechnol 28: 495–501
Trapnell C, Roberts A, Goff L et al (2012) Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc 7:562–578
Smyth GK (2004) Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3, Article 3
Rosenbloom KR, Dreszer TR, Pheasant M et al (2010) ENCODE whole-genome data in the UCSC Genome Browser. Nucleic Acids Res 38:D620–D625
Handel AE, Sandve GK, Disanto G et al (2013) Integrating multiple oestrogen receptor alpha ChIP studies: overlap with disease susceptibility regions, DNase I hypersensitivity peaks and gene expression. BMC Med Genomics 6:45
Paulsen J, Sandve GK, Gundersen S et al (2014) HiBrowse: multi-purpose statistical analysis of genome-wide chromatin 3D organization. Bioinformatics 30:1620–1622
Grant CE, Bailey TL, Noble WS (2011) FIMO: scanning for occurrences of a given motif. Bioinformatics 27:1017–1018
Welboren W-J, van Driel MA, Janssen-Megens EM et al (2009) ChIP-Seq of ERalpha and RNA polymerase II defines genes differentially responding to ligands. EMBO J 28:1418–1428